22. January 2010 00:53
Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.
[More]
8aa11a1d-51bb-449d-bb41-bd15421e90d4|0|.0
Posted in: Business / Finance
Tags: Acarbose, Benign Prostatic Hyperplasia, Cancer, Ciprofloxacin, Contraception, Cystitis, Drug Delivery, Infertility, Medicaid, Medicare, Overactive Bladder, Prostate Cancer, Ramipril, Urology
11. January 2010 23:43
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH), a painful and bothersome urological condition that affects more than 50 million men worldwide.
[More]
e0220411-874d-4593-be2d-cce6e93b3d9a|0|.0
Posted in: Men's Health News | Drug Trial News
Tags: Benign Prostatic Hyperplasia, Brain, Brain Cancer, Cancer, Cell, Incontinence, Prostate Cancer, Prostate-Specific Antigen, Sexual Dysfunction, Ultrasound, Urology
6. January 2010 05:33
According to a new global report series by iData Research, the leading authority in medical device, dental and pharmaceutical market research, the U.S. market for urological devices is estimated to more than double in value by 2016, reaching over $5.4 billion.
[More]
30. December 2009 23:38
This new year, make a resolution to improve your health and talk to your doctor about urologic conditions. Although urologic problems may seem embarrassing to talk about, these conditions are more common than you think and a delay in seeking medical attention could cause you unnecessary stress, prolong the problem and even increase your risk for a more serious condition.
[More]
1e98063b-060d-4de6-b2ac-fbcaf8d245cb|0|.0
Posted in: Medical Condition News
Tags: Benign Prostatic Hyperplasia, Blood Pressure, Cancer, Childbirth, Cholesterol, Constipation, Diabetes, Diabetes Mellitus, Erectile Dysfunction, Incontinence, Premature Ejaculation, Prolapse, Prostate Cancer, Puberty, Septicemia, Skin Cancer, Stress
21. December 2009 10:51
Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.
[More]
60d3ab30-cd56-4315-9fa4-efc8a6cdf529|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anxiety, Benign Prostatic Hyperplasia, Brain, Chorea, Depression, Diabetes, Dopamine, Dystonia, Endometriosis, Histamine, Irritable Bowel Syndrome, New Drug Application, Schizophrenia, Serotonin, Tardive Dyskinesia
18. December 2009 07:40
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.
[More]
17844858-db6a-407c-a424-40054b4f4d8f|0|.0
Posted in: Business / Finance | Pharmaceutical News
Tags: Benign Prostatic Hyperplasia, Cancer, Cetrorelix, Doxorubicin, Endocrinology, Ghrelin, Growth Hormone, Hormone, Multiple Myeloma, Oncology, Perifosine
17. December 2009 06:34
Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.
[More]
10. December 2009 07:19
At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.
[More]
ce8f807a-b020-422d-9179-197f6b085fc5|1|4.0
Posted in: Business / Finance
Tags: Adcirca, Alimta, Alzheimer's Disease, Antibody, Antidepressant, Antisense, Arthritis, Autoimmune Disease, Benign Prostatic Hyperplasia, Biotechnology, Brain, Breast Cancer, Cancer, Cell, Cetuximab, Colorectal Cancer, Cymbalta, Depression, Diabetes, Diabetes Mellitus, DNA, Duloxetine, Effient, Exenatide, Gemcitabine, Gemzar, Glioblastoma, Head and Neck Cancer, Hospital, Insomnia, Insulin, Investment, Leukemia, Lung Cancer, Lymphoma, Melanoma, Migraine, Monoclonal Antibody, Multiple Sclerosis, Myeloid Leukemia, Neuroscience, Non-Small Cell Lung Cancer, Olanzapine, Oncology, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Pemetrexed, Prasugrel, Prostate Cancer, Pulmonary Arterial Hypertension, Recombinant DNA, Rheumatoid Arthritis, Schizophrenia, Small Cell Lung Cancer, Type 1 Diabetes, Zyprexa
10. December 2009 05:40
Urodynamix Technologies Ltd. today announces that its Board of Directors has initiated a process to review strategic alternatives including the sale of part of or all of the Company's assets.
[More]
10. December 2009 03:05
In men undergoing prostate surgery, excessive fluid absorption can lead to dangerously low sodium levels. Adding a small amount of glucose to the irrigation fluid used during surgery can help anesthesiologists to prevent this rare but potentially serious complication, reports a study in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
[More]
10. December 2009 02:29
Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.
[More]
500fa26b-2ca7-4c8b-9bb6-68551d6b8c95|0|.0
Posted in: Drug Trial News | Women's Health News
Tags: Anxiety, Benign Prostatic Hyperplasia, Bone, Bone Mineral Density, Depression, Diabetes, Endometriosis, Gonadotropin, Headache, Hormone, Hot Flash, Irritable Bowel Syndrome, Nausea
9. December 2009 09:22
Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.
[More]
7. December 2009 23:34
AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.
[More]
7. December 2009 08:31
Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.
[More]
23. November 2009 10:33
Urodynamix Technologies Ltd. today announced that the American Medical Association (AMA) has published its 2010 Current Procedural Terminology (CPT) codes with additions, changes and deletions of billing codes for all medical specialities including urology.
[More] 
Subscribe